Maternal care for anti-D [Rh] antibodies, first trimester (other fetus)
ICD-10 O36.0119 is a billable code used to indicate a diagnosis of maternal care for anti-d [rh] antibodies, first trimester (other fetus).
O36.0119 refers to maternal care for women who have developed anti-D (Rh) antibodies during the first trimester of pregnancy, specifically when the fetus is not the primary focus of care. This condition arises when an Rh-negative mother is exposed to Rh-positive blood, leading to the production of antibodies that can affect the fetus. The presence of these antibodies can lead to complications such as hemolytic disease of the newborn, fetal growth restriction, and fetal distress. Monitoring and management of the pregnancy are crucial to mitigate risks associated with these antibodies. Care may involve regular ultrasounds to assess fetal growth, non-stress tests to monitor fetal heart rate, and potentially intrauterine transfusions if severe anemia is detected. The management plan should be tailored to the specific needs of the mother and fetus, considering the potential for complications arising from the maternal antibodies.
Documentation must include maternal blood type, antibody screening results, and any interventions performed.
Management of a pregnant woman with a history of Rh sensitization, monitoring for fetal distress, and growth restriction.
Consideration of the mother's obstetric history and any previous pregnancies affected by Rh incompatibility.
Detailed records of high-risk assessments, including ultrasound findings and fetal monitoring results.
Complex cases involving multiple fetal assessments due to suspected anemia or growth restriction.
Coordination with neonatology for potential interventions at delivery.
Used for monitoring fetal growth and well-being in patients with anti-D antibodies.
Documentation of ultrasound findings and any interventions based on results.
Obstetricians should ensure that ultrasound reports are detailed and correlate with the diagnosis.
Coding O36.0119 is crucial for identifying pregnancies at risk due to maternal anti-D antibodies, allowing for appropriate monitoring and management to prevent complications such as fetal distress and growth restriction.
